Human Plasmacytoid Dendritic Cells (PDCs) infiltrating solid tumor tissues and draining lymph nodes of Head and Neck Squamous Cell Carcinoma (HNSCC) show an impaired immune response. In addition to an attenuated secretion of IFN-α little is known about other HNSCC-induced functional alterations in PDCs. Particular objectives in this project were to gain new insights regarding tumor-induced phenotypical and functional alterations in the PDC population. We showed by FACS analysis and RT-PCR that HNSCC orchestrates an as yet unknown subpopulation exhibiting functional autonomy in-vitro and in-vivo besides bearing phenotypical resemblance to PDCs and T cells. A subset, positive for the PDC markers CD123, BDCA-2, HLA-DR and the T cell receptor αβ (TCR-αβ) was significantly induced subsequent to stimulation with HNSCC in-vitro (p = 0.009) and also present in metastatic lymph nodes in-vivo. This subgroup could be functionally distinguished due to an enhanced production of IL-2 (p = 0.02), IL-6 (p = 0.0007) and TGF-β (not significant). Furthermore, after exposure to HNSCC cells, mRNA levels revealed a D-J-beta rearrangement of the TCR-beta chain besides a strong enhancement of the CD3ε chain in the PDC population. Our data indicate an interface between the PDC and T cell lineage. These findings will improve our understanding of phenotypical and functional intricacies concerning the very heterogeneous PDC population in-vivo.
Citation: Thiel A, Kesselring R, Pries R, Puzik A, Wittkopf N, Wollenberg B (2011) Expression of the T Cell Receptor αβ on a CD123+ BDCA2+ HLA-DR+ Subpopulation in Head and Neck Squamous Cell Carcinoma. PLoS ONE 6(1): e15997. doi:10.1371/journal.pone.0015997
Editor: Torbjorn Ramqvist, Karolinska Institutet, Sweden
Received: September 7, 2010; Accepted: December 2, 2010; Published: January 11, 2011
Copyright: © 2011 Thiel et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by grants from the Mildred Scheel-Stiftung (Deutsche Krebshilfe), the Werner-and-Klara-Kreitz-Stiftung, the Monika-Kutzner-Stiftung and the Rudolf-Bartling-Stiftung. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing interests: The authors have declared that no competing interests exist.
Dendritic cells (DCs) are bone marrow derived antigen presenting cells, such as B cells and monocytes and appear to be indispensable for initiating appropriate immune responses. A complicated trafficking system leads them from the bone marrow through the bloodstream to distinct peripheral tissues, where different immature DC populations reveal unique kinds of chemokine responsiveness . Finally they migrate to lymphoid organs in order to present processed antigens to lymphocytes and to stimulate immune responses . Two main human DC subsets are to be distinguished: myeloid dendritic cells (MDCs) including Langerhans cells, dermal dendritic cells and interstitial DCs versus plasmacytoid dendritic cells (PDCs) . Referring to their plasma cell-like appearance PDCs were first identified as ‘Plasmacytoid monocytes/T cells’ in T cell areas of lymphoid organs, later also in peripheral blood and tonsils .
PDCs are to a small extent capable of presenting antigens to T cells, however their main known function is characterized by the ability to produce large amounts of IFN-α in viral infections in-vivo. In-vitro, IFN-α secretion is also triggered by CpG-oligonucleotides, which consist of unmethylated CpG-dinucleotides embedded in a certain sequence context within bacterial DNA , , . Recently, different PDC subsets with distinct phenotype und functions have been identified , .
It has been shown that human solid tumor tissues of Head and Neck Squamous Cell Carcinoma (HNSCC) are infiltrated by PDCs, which seem to intensely compromise proper immune functions in this environment . Cells of head and neck cancer are known to develop molecular strategies to escape from efficient anti-tumor immune responses. Up to now it was assumed that mainly production of various immunosuppressive mediators by tumor cells contributes to a heavily deranged immune defence .
However, the molecular mechanisms responsible for these immunomodulatory transformation processes and the biosynthesis of the immunosuppressive HNSCC microenvironment remain almost unknown , . In this work we present a new approach to the subject by introducing a novel, functionally distinct subpopulation bearing phenotypical resemblance to PDCs and T cells in HNSCC.
Phenotypical alterations in the PDC population subsequent to incubation with HNSCC cell-lines in-vitro were narrowed to incomplete maturation and up-regulation of the receptors CD4 and CD45RA
Classical PDC maturation is phenotypically defined by the up-regulation of CD123, CD80, CD83, CD86 and HLA-DR in addition to the down-regulation of the C-type Lectin BDCA-2 , , . However, subsequent to incubation with permanent HNSCC cell-lines for 12 hours, PDCs show only a partial maturation. Unlike classical maturation, HNSCC has neither any impact on HLA-DR nor on the co-receptors CD80, CD83 and CD86. BDCA-2 was significantly down-regulated (p = 0.01), while CD123 was up-regulated (p = 0.07). In some donors HLA-DR was strongly down-regulated. Furthermore, a highly significant surface elevation of CD4 (p = 0.009) and CD45RA (p = 0.001) was observed (Figure 1A).
A CD123+ HLA-DR+ BDCA-2+ cells showed an incomplete maturation subsequent to stimulation with HNSCC. BDCA-2 was down-regulated (p = 0.011) while CD123 was up-regulated (p = 0.07). Furthermore, a highly significant up-regulation of CD4 (p = 0.009) and CD45RA (p = 0.001) was observed. B TCR-αβ positive, CD123+ HLA-DR+ BDCA-2+ cells were significantly (p = 0.009) induced subsequent to stimulation with HNSCC cell-lines for 12 hours. The Mean Fluorescence Intensity (MFI) was determined separately for each Isotype control and each subpopulation and then subtracted from the positive results before calculating the relative MFI. Figure 1 shows the relative MFI after incubation with HNSCC in relation to the medium control MFI. The control MFI is equal to 1 in each case by definition. The data are presented in box plots, showing the median, the lower and the upper quartile.
All other analysed receptors, which were lineage markers (CD3, CD14, CD16, CD19, CD20, CD56), Fc-receptors (CD16, CD23, CD32, CD64), further T cell markers (CD1a, CD2, CD3, CD5, CD8, CD25, GITR, CTLA-4), activation markers (CD40, CD69), stem cell markers (CD34, CD117, CD133) and the myeloid marker CD11c, were not significantly affected by tumor cell-lines in the classical PDC population (data not shown).
HNSCC induced a TCR-αβ positive CD123+ BDCA2+ HLADR+ subset
HNSCC induced a TCR-αβ positive CD123+ BDCA2+ HLADR+ subset. This subset was significantly (p = 0.009) up-regulated subsequent to stimulation with HNSCC cell-lines for 12 hours and enhanced from 1.6% (mean) +/−1.5% (SD) in the medium control to 4.5% (mean) +/−0.88% (SD) after stimulation (Figure 1B). Furthermore it was located in the centre of the PDC population when back-gated to the FACS forwards/sidewards scatter (Figure 2) and exhibited a double-positive phenotype for CD4 and CD8 in-vitro, however, partly a double-negative phenotype in-vivo (data not shown). Furthermore, this subset was positive for CD2, CD3, CD5 and CD7 (Figure 3). CD1a, CTLA-4, FOXP3, CD34 and CD117 were not expressed. Some donors revealed CD25dim+/TCR-αβ+ cells, however we could not show any significance for the expression of the surface marker CD25. CD25 positive cells were likewise located in the PDC region (SSC/FSC) and represented larger cells than the remaining TCR-αβ positive subset (Text S1). Doublets were excluded by gating FSC-H against FSC-A. The TCR-γ/δ could not be detected.
An IgM-Isotype control was used as a negative control. Cell viability was confirmed by staining with Annexin and PI. TCR-αβ positive cells were significantly (p = 0.009) enhanced from 1.6% (mean) +/−1.5% (SD) in the medium control to 4.5% (mean) +/−0.88% (SD) in healthy donors after stimulation with tumor in-vitro. The TCR positive subset expressed the surface markers CD123, HLA-DR (not shown) and BDCA2 and was located in the centre of the PDC population when back gated to FSC/SSC. The black dots represent the TCR-αβ positive cells in the lower scattergrams.
The TCR-αβ positive subset expressed the surface markers CD2, CD3, CD4, CD5, CD7 and CD8.
Furthermore a RT-PCR was performed subsequent to stimulating and cell-sorting the PDC population. Compared to the medium control, a distinct up-regulation of CD3ε and the pre-TCRα mRNA was detected after incubation with HNSCC. CD3γ and CD3δ mRNA could not be detected. As T cells do express CD3γ and CD3δ mRNA, these lanes were used as a control in order to exclude a contamination by ordinary T cells.
Furthermore the data comprise a strong indication for the up-regulation of the recombined D-J-β chain in the PDC population subsequent to stimulation with HNSCC cell-lines (Figure 4).
We demonstrated an increase of the pre-TCRα-receptor mRNA-levels besides a strong enhancement of the CD3ε chain mRNA-levels after stimulation with HNSCC in the PDC population. Both, the CD3δ and γ chain were not detectable. In order to prove recombination of the TCR-β chain in the PDC population, we also analysed mRNA up-regulation for D-J-β, the earliest point of recombination of the TCR-β chain. Indeed, after stimulation with tumor we did detect D-J-β mRNA. For a positive control PDC depleted PBMCs were used in order to demonstrate the presence of CD3δ and γ mRNA in contrast to the isolated CD123+ HLA-DR+ BDCA-2+ population. The pre-TCRα mRNA could hardly be detected.
The TCR-αβ positive CD123+ HLA-DR+ BDCA-2+ cells revealed distinct functional properties in-vitro and in-vivo
We analysed the cytokine production (IL-2, IL-4, IL-6, IL-8, IL-10 and TGF-β) of the TCR-αβ positive subset in-vitro and in single cell suspensions of metastatic lymph nodes from HNSCC patients. The results were compared to the cytokine production of the TCR-αβ negative PDC population. We were able to significantly demonstrate a higher intracellular production of IL-2 and IL-6 in the TCR-αβ positive PDC population in-vitro and in-vivo (p = 0.02). A dominant IL-6 secretion was highly significant (p = 0.0007) for the TCR-αβ positive cells in-vivo (Figure 5 and 6). 90–100% of the TCR-αβ+ cells were positive for IL-2 and 100% of the TCR-αβ+ cells were positive for IL-6 in each sample (p<0.001). The classical PDCs do not confidently produce IL-2. The FACS plots show a shift in the population, however no circumscribable positive subset. About 80% of the classical PDCs were positive for IL-6 (p<0.001).
The TCR-αβ positive cells produced higher levels of IL-2 and IL-6 when compared to the TCR-αβ negative CD123+ HLA-DR+ BDCA-2+ cells. All results were significant (p = 0.02), a dominant IL-6 secretion (p = 0.0007) was highly significant for the TCR-αβ positive cells in-vivo. The Mean Fluorescence Intensity (MFI) was determined separately for each Isotype control and each subpopulation and then subtracted from the positive results before calculating the relative MFI. Figure 5 shows the relative MFI of the TCR-αβ positive subset in relation to the MFI of the classical PDC population. The MFI of the classical PDC population is equal to 1 in each case by definition. The data are presented in box plots, showing the median, the lower and the upper quartile.
FACS plots showing IL-2 and IL-6 production in-vivo. The black circles identify the TCR-αβ positive population. In this sample, the TCR-αβ positive cells comprised 2% of the PDC population and partly produced TGF-β. TGF-β secretion was analysed four times.
Expansion of the TCR-αβ subset could not be demonstrated
Expansion of the TCR-αβ+ subset could not be assured, as the TCR-αβ was barely detectable after cross-linking CD3/28. Nevertheless, we incubated isolated CD123+ BDCA-2+ HLA-DR+ cells with HNSCC and the T cell Expansion Kit (Miltenyi) in addition to IL-2 (20–200 U/l) for 3–7 days. Less TCR-αβ+ cells were revealed (after 1–7 days) when compared to the control with HNSCC after 24 h (Figure 7). Presumably this can be attributed to the down-regulation of the TCR subsequent to cell activation. However, the CD123+ BDCA-2+ HLA-DR+ cells, which usually do not survive longer than 12–24 hours in-vitro, survived up to 7 days subsequent to stimulation with the Expansion Kit and IL-2. Incubation with IL-4 (1–10 pg/ml), IL-6 (500–4000 pg/ml), IL-8 (500–1000 pg/ml), IL-10 (10 ng/ml) and TGF-β (10 ng/ml) did not lead to any significant expansion of the subset. Cytokine concentrations were chosen according to the cytokine secretion of the HNSCC cell lines, which induced the TCR-αβ+ subset .
Less TCR-αβ+ cells were revealed (after 1-7 days) when compared to the control with HNSCC after 24 h. Presumably this can be attributed to the down-regulation of the TCR subsequent to cell activation.
The transcription factor Notch-1 is up-regulated in the PDC population subsequent to incubation with HNSCC cell-lines
As the transcription factors Notch-1, GATA-3 and SPI-B have been shown to control the T cell/PDC lineage decision in early thymocytes , the mRNA levels were analysed in the PDC population after stimulation with HNSCC. Indeed, we found elevated levels of Notch-1 mRNA, however no up-regulation of GATA-3 and SPI-B mRNA could be detected (Figure 4).
Numerous pro-inflammatory, pro-angiogenetic and immuno-suppressive cytokines , , ,  within the HNSCC microenvironment and in the serum of tumor patients are suspected of benefiting tumor growth and metastasis besides severely impairing the function of various immune cells , , . Especially IL-6, correlating with tumor stage and lymph node status , has been proven to be an independent predictor of poor survival . Solid HNSCC and metastatic lymph nodes have been found to be infiltrated by various species of immune cells including PDCs, which are supposed to participate in the formation of the HNSCC microenvironment due to functional alterations , , .
PDCs in HNSCC
In accordance with the postulation above, we observed functionally disabled PDCs after stimulation with tumor. As already revealed in non-small cell lung cancer  we concordantly demonstrated an impaired phenotypical maturation in the PDC population in-vivo and after stimulation with HNSCC cell-lines for 12 hours in-vitro.
Consistent with normal maturation CCR7  and CD123 are up-regulated whilst BDCA2 is down-regulated. In contrast the co-stimulatory receptors (CD80, CD86) and CD83 are not influenced by the tumor, HLA-DR expression is even decreased in many cases and the early activation marker CD25  is only presented by a small subpopulation [unpublished data]. As we have already shown in earlier studies, the immature phenotype also correlates with a disturbed functional maturation. PDCs stimulated with CpG-2216 reveal an impaired IFN-α production in the HNSCC environment .
TCR-αβ positive CD123+ HLA-DR+ BDCA-2+ cells in HNSCC
First of all the discovery of the TCR-αβ on a subpopulation of CD123+ HLA-DR+ BDCA-2+ cells confronted us with two main questions: did we really find a new population expressing the TCR and not activated, blastic T cells similar to the recently characterised CD4+ Th-APC ? Furthermore, as Busch et al.  discovered the transfer of T cell surface molecules to DCs upon CD4+ T cell priming: did we observe a TCR exchange or production?
Therefore we performed a RT-PCR for the earliest point of recombination: the DJ-β chain, for the CD3 chains and the pre-TCRα. After stimulation with HNSCC cell-lines, a weak induction of the DJ-β chain was exhibited whilst no trace was visible in the medium control. The other striking point is the difference in the distribution of the CD3 chains and the pre-TCRα in the PDC population compared to the PBMC control. Whilst the lymphocytes in the PBMC control express the CD3δ, ε and γ chain mRNA, the PDC population only exhibits a weak expression of the CD3ε chain which is clearly enhanced after stimulation. Similar results are demonstrated for the pre-TCRα mRNA. These findings indicate an intracellular production of parts of the T cell receptor and exclude a contamination by ordinary T cells.
Due to the size of the TCR positive subpopulation, the FACS facility was not able to reach a high purity by cell sorting this subset, so we had to reduce functional analyses to the FACS. Currently we are working on expanding cocktails for this subpopulation.
By FACS analysis we were able to demonstrate significantly higher amounts of intracellular IL-2 and IL-6 for the TCR positive subpopulation. Especially production of IL-6 was highly significant in-vivo. Furthermore, the production of TGF-β was observed in the TCR positive subset. Therefore, we postulate a role for this population in tumor growth, metastasis and induction of tolerance. IL-6 and likewise CD25/HLA-DR+ T cells, which are at least phenotypically associated with the new subpopulation, have been proven to be a predictor of poor survival in HNSCC , . Additionally, IL-6 promotes growth, survival, invasiveness and also secretion of IL-6 in different tumors in-vivo , , . Furthermore, also the secretion of TGF-β has been linked to epithelial-mesenchymal transition, metastasis and the induction of oncogenic properties , ,  besides impairing the secretion of IFN-α in PDCs . Doubtless, these postulations are speculative at the time. However, as Baban et al. and Matsui et al. ,  have already demonstrated functionally distinct PDC subsets, we consider it possible that this minor subset has a relevant impact on HNSCC.
Origin of the subpopulation
A further question concerns the cell lineage of this subpopulation. The TCR positive CD123+ HLA-DR+ BDCA-2+ cells may originate from a T cell subpopulation exhibiting PDC features besides lacking the CD3 δ and γ chain. Likewise they may originate from a subpopulation of PDCs. Similar to other recently discovered populations showing an interface between two lineages , , a determination of the lineage will become a major challenge, as a mutual contamination cannot be absolutely excluded during isolation. A possible approach could include the detection of IFN-α and the transcription factor E2-2 .
As NOTCH-1 has been shown to regulate PDC versus T cell lineage decision through control of GATA-3 and SPI-B  we analysed the mRNA levels of the PDC population subsequent to stimulation. However, although NOTCH-1 mRNA was up-regulated after exposure to HNSCC cell-lines, we could not demonstrate any expression of GATA-3. On the contrary, the levels of SPI-B, which is supposed to inhibit T-, NK- and B cell development , were actually slightly elevated. In this respect we were able to exclude the relevance of this pathway for the TCR positive subpopulation.
Besides expanding the new subset for functional analysis versus demonstrating their relevance as non-proliferating bystander T cells , determination of the lineage and functional analysis of the TCR signalling, in-vivo models will have to clarify the relevance of this population in HNSCC.
Materials and Methods
An ethic proposal concerning the abstraction of tumor tissue during operations of tumor patients was approved by the ethics committee, Campus Lübeck. All experiments have been conducted according to the principles expressed in the Declaration of Helsinki. Written informed consent was obtained in each case before abstracting tissue and blood (Text S2, S3, S4).
Isolation of PDCs
For in-vitro studies PDCs were isolated from human peripheral blood provided by the blood bank of the University Hospital Lübeck, Germany. Blood donors were 18–65 year-old healthy donors who were tested to be negative for allergies. Additional exclusion-criteria were manifest infections during the last 4 weeks, fever or medication of any kind. Peripheral mononuclear blood cells (PBMCs) were obtained from buffy coats by Ficoll-Hypaque density gradient centrifugation as described elsewhere . PDCs were isolated by magnetic bead separation using magnetic labelled anti-BDCA-4 antibodies (Miltenyi, Bergisch Gladbach, Germany).
After removal of fat, blood or necrotic areas, tumor draining lymph nodes were washed in phosphate buffered saline (PBS), cut into little pieces in a Petri dish covered with PBS and washed again with PBS by gravity sedimentation in a 50 ml conical centrifuge tube. The tissue pieces were then covered with 31,5 mg Collagenase/ml PBS and 3,99 mg/ml Hyaloronidase/ml PBS in DMEM and incubated in a 37°C water bath for 30–120 minutes. Digestion was checked every 30 minutes. In a further step 33,4 mg Dispase/ml PBS was added for 30–60 minutes. Brefeldin A (eBioscience, San Diego, USA) was supplied during all steps. The digest was then passed through a 100 µm nylon mesh in order to remove clumps and washed several times.
The permanent HNSCC cell lines BHY (DSMZ Germany), PCI-1 and PCI-13 (generously provided by Prof. T. Whiteside, Pittsburgh Cancer Institute) were cultured in Dulbecco’s Modified Eagle Medium (DMEM, Gibco, New York, USA) supplemented with 10% FCS, 1 mM glutamine, and 0.1 mM sodium pyruvate. All compounds were purchased Endotoxin tested.
Depending on the amount of cells, PDCs were incubated with HNSCC supernatants or co-cultured with the tumor cell-lines BHY, PCI-1 and PCI-13 at a concentration of 480000cells/60 µl in U-shaped 96 well plates or flat bottomed 12 well plates for 12 hours. For cell expansion, the T cell Expansion Kit (Miltenyi) was applied according to the manufacturing protocol. The cytokines IL-2 (20–200 U/l, BD), IL-4 (1–10 pg/ml, BD), IL-6 (500–4000 pg/ml, BD), IL-8 (500–1000 pg/ml, BD), IL-10 (10 ng/ml, BD) and TGF-β (10 ng/ml, BD) were added for 1–7 days.
PDCs were identified as CD123-PE positive, HLA-DR-PerCP positive, lineage cocktail-FITC (CD3, CD14, CD16, CD19, CD20, CD56; Becton Dickinson Heidelberg, Germany) negative and BDCA2-APC/PE (Miltenyi Biotec, Bergisch-Gladbach, Germany) positive cells. Surface antigen staining was performed using the antibodies CD1a-FITC, CD2-PE, CD3-PE, CD4-PERCP, CD4-APC-CY7, CD8-ARC-CY7, CD11c-APC, CD14-APC, CD16-FITC, CD19-FITC, CD20-APC, CD23-PE, CD-25-APC/APC-CY7, CD32-FITC, CD34-PERCP, CD38-APC/PE-CY7, CD40-APC, CD44-PE, CD56-PE, CD64-FITC, CD69-FITC, CD80-FITC, CD83-FITC, CD86-PE, CTLA4-PE, CCR7-PE-CY7, CD117-APC, TCR-α/β-PE/FITC, TCR-γ/δ -APC, IFNg-FITC, IL-4 PE, IL-10 APC (Becton Dickinson Heidelberg, Germany), CD123-APC/FITC, BDCA4-APC, CD45RA-FITC, CD133-PE (Miltenyi Biotec, Bergisch-Gladbach, Germany), CD25-FITC/PE-CY7, CD127-FITC, (eBioscience, San Diego, USA) and GITR-FITC, IL-2 FITC, IL-6-FITC, IL-8-FITC, TGF-β-PE, TNF-α-FITC (R&D Systems, Minneapolis, USA). The Isotype PE IgG1/IgG2a, the Isotype APC IgG1/IgG2a and the Isotype Fitc IgG1/IgG2b (Becton Dickinson, Heidelberg, Germany) were used as negative controls. The Mean Fluorescence Intensity (MFI) was determined separately for each Isotype control and each subpopulation and then subtracted from the positive results before calculating the relative MFI. The figures 1 and 4 show the relative MFI after incubation with HNSCC in relation to the medium control MFI and to the MFI of the classical PDC population (negative for the TCR-αβ), respectively. The control MFI is equal to 1 in each case by definition. Early apoptotic or dead cells were detected by staining the cells with Annexin-V-FITC and Propidium-Iodide-PE (Becton Dickinson, Heidelberg, Germany). Doublets were excluded by gating FSC-A against FSC-H. Only singlets were analysed. CD107a was up-regulated in the PDC population subsequent to stimulation with HNSCC, indicating cytokine secretion.
The amount of 2·105 PDCs was incubated on ice in 50 µl 1% BSA (in PBS) with 1-2 µl of each antibody for 15 minutes. Then the cells were washed three times in 500 µl 1% BSA and subsequently analysed on a FACSCanto (Becton Dickinson) equipped with FACS DIVA software. Intracellular staining was performed with the eBioscience-staining-buffer-set according to the eBioscience protocol. Cell sorting was performed with a Dako moFlow.
After cell-sorting and verification of cell purity and viability, mRNA was isolated with the RNeasy kit (Qiagen, Hilden, Germany). For RT-PCR we used the Qiagen One-step RT-PCR kit according to protocol and publications. The primers are listed in table 1. In order to minimize the risk of falsified results by proliferating cells, RT-PCR was performed directly after sorting the PDC population. Stimulated PDCs we isolated at a purity >99%, PDCs in the medium control at a purity >92%.
Subsequent to electrophoresis, the PCR products were sequenced at the University of Kiel.
Statistical analysis and samples
The Kolmogorow-Smirnow test did not show a normal distribution. Therefore we performed the Wilcoxon-Mann-Withney test for statistical analysis. p<0.05 was considered to be marginally significant. 5–12 samples were analysed per surface marker, cytokine and tissue. Only those FACS plots showing a clear separation between the subpopulations were included. Doublets were excluded by gating FSC-A against FSC-H. Cells were extracted from the blood of healthy donors and metastatic lymph nodes. Solid tumor tissue did not provide PDCs sufficiently for cytokine analysis. Tissue histology was determined by the Institution for Pathology, University of Lübeck.
Supporting information on the TCR-αβ positive population.
An ethic proposal concerning the abstraction of tumor tissue during operations of tumor patients was approved by the ethics committee, Campus Lübeck.
Written informed consent was obtained in each case before abstracting tissue and blood.
Written informed consent was obtained in each case before abstracting tissue and blood.
We thank Tillmann Vollbrandt (FACS sorting facility), Veronica Bernard (Department of Human Genetics) and Carsten Brocks (M.D., Otorhinolaryngology) for skillful support in some parts of this work. We are grateful to all members of the Department of Otorhinolaryngology.
Conceived and designed the experiments: AT RP BW. Performed the experiments: AT RK NW. Analyzed the data: AT AP. Contributed reagents/materials/analysis tools: RP BW AP. Wrote the paper: AT.
- 1. Sozzani S (2005) Dendritic cell trafficking: more than just chemokines. Cytokine Growth Factor Rev 16: 581–592.
- 2. Dieu MC, Vanbervliet B, Vicari A, Bridon JM, Oldham E, et al. (1998) Selective recruitment of immature and mature dendritic cells by distinct chemokines expressed in different anatomic sites. J Exp Med 188: 373–386.
- 3. McKenna K, Beignon AS, Bhardwaj N (2005) Plasmacytoid dendritic cells: linking innate and adaptive immunity. J Virol 79: 17–27.
- 4. Facchetti F, de Wolf-Peeters C, van den Oord JJ, de Vos R, Desmet VJ (1989) Plasmacytoid monocytes (so-called plasmacytoid T cells) in Kikuchi's lymphadenitis. An immunohistologic study. Am J Clin Pathol 92: 42–50.
- 5. Meyers JH, Justement JS, Hallahan CW, Blair ET, Sun YA, et al. (2007) Impact of HIV on cell survival and antiviral activity of plasmacytoid dendritic cells. PLoS One 2: e458.
- 6. Rothenfusser S, Tuma E, Endres S, Hartmann G (2002) Plasmacytoid dendritic cells: the key to CpG. Hum Immunol 63: 1111–1119.
- 7. Tel J, Lambeck AJ, Cruz LJ, Tacken PJ, de Vries IJ, et al. (2010) Human plasmacytoid dendritic cells phagocytose, process, and present exogenous particulate antigen. J Immunol 184: 4276–4283.
- 8. Baban B, Chandler PR, Sharma MD, Pihkala J, Koni PA, et al. (2009) IDO activates regulatory T cells and blocks their conversion into Th17-like T cells. J Immunol 183: 2475–2483.
- 9. Matsui T, Connolly JE, Michnevitz M, Chaussabel D, Yu CI, et al. (2009) CD2 distinguishes two subsets of human plasmacytoid dendritic cells with distinct phenotype and functions. J Immunol 182: 6815–6823.
- 10. Hartmann E, Wollenberg B, Rothenfusser S, Wagner M, Wellisch D, et al. (2003) Identification and functional analysis of tumor-infiltrating plasmacytoid dendritic cells in head and neck cancer. Cancer Res 63: 6478–6487.
- 11. Pries R, Wollenberg B (2006) Cytokines in head and neck cancer. Cytokine Growth Factor Rev 17: 141–146.
- 12. Chin D, Boyle GM, Theile DR, Parsons PG, Coman WB (2004) Molecular introduction to head and neck cancer (HNSCC) carcinogenesis. Br J Plast Surg 57: 595–602.
- 13. Douglas JG, Koh W, Laramore GE (2000) Metastasis to a percutaneous gastrostomy site from head and neck cancer: radiobiologic considerations. Head Neck 22: 826–830.
- 14. Dzionek A, Fuchs A, Schmidt P, Cremer S, Zysk M, et al. (2000) BDCA-2, BDCA-3, and BDCA-4: three markers for distinct subsets of dendritic cells in human peripheral blood. J Immunol 165: 6037–6046.
- 15. Gibson SJ, Lindh JM, Riter TR, Gleason RM, Rogers LM, et al. (2002) Plasmacytoid dendritic cells produce cytokines and mature in response to the TLR7 agonists, imiquimod and resiquimod. Cell Immunol 218: 74–86.
- 16. Krug A, Towarowski A, Britsch S, Rothenfusser S, Hornung V, et al. (2001) Toll-like receptor expression reveals CpG DNA as a unique microbial stimulus for plasmacytoid dendritic cells which synergizes with CD40 ligand to induce high amounts of IL-12. Eur J Immunol 31: 3026–3037.
- 17. Pries R, Thiel A, Brocks C, Wollenberg B (2006) Secretion of tumor-promoting and immune suppressive cytokines by cell lines of head and neck squamous cell carcinoma. In Vivo 20: 45–48.
- 18. Dontje W, Schotte R, Cupedo T, Nagasawa M, Scheeren F, et al. (2006) Delta-like1-induced Notch1 signaling regulates the human plasmacytoid dendritic cell versus T cell lineage decision through control of GATA-3 and Spi-B. Blood 107: 2446–2452.
- 19. Chen Z, Malhotra PS, Thomas GR, Ondrey FG, Duffey DC, et al. (1999) Expression of proinflammatory and proangiogenic cytokines in patients with head and neck cancer. Clin Cancer Res 5: 1369–1379.
- 20. Szczepanski MJ, Czystowska M, Szajnik M, Harasymczuk M, Boyiadzis M, et al. (2009) Triggering of Toll-like receptor 4 expressed on human head and neck squamous cell carcinoma promotes tumor development and protects the tumor from immune attack. Cancer Res 69: 3105–3113.
- 21. Bose A, Chakraborty T, Chakraborty K, Pal S, Baral R (2008) Dysregulation in immune functions is reflected in tumor cell cytotoxicity by peripheral blood mononuclear cells from head and neck squamous cell carcinoma patients. Cancer Immun 8: 10.
- 22. Lathers DM, Achille NJ, Young MR (2003) Incomplete Th2 skewing of cytokines in plasma of patients with squamous cell carcinoma of the head and neck. Hum Immunol 64: 1160–1166.
- 23. Sparano A, Lathers DM, Achille N, Petruzzelli GJ, Young MR (2004) Modulation of Th1 and Th2 cytokine profiles and their association with advanced head and neck squamous cell carcinoma. Otolaryngol Head Neck Surg 131: 573–576.
- 24. Riedel F, Zaiss I, Herzog D, Gotte K, Naim R, et al. (2005) Serum levels of interleukin-6 in patients with primary head and neck squamous cell carcinoma. Anticancer Res 25: 2761–2765.
- 25. Duffy SA, Taylor JM, Terrell JE, Islam M, Li Y, et al. (2008) Interleukin-6 predicts recurrence and survival among head and neck cancer patients. Cancer 113: 750–757.
- 26. Heimdal JH, Aarstad HJ, Olofsson J (2000) Peripheral blood T-lymphocyte and monocyte function and survival in patients with head and neck carcinoma. Laryngoscope 110: 402–407.
- 27. Heimdal JH, Kross K, Klementsen B, Olofsson J, Aarstad HJ (2008) Stimulated monocyte IL-6 secretion predicts survival of patients with head and neck squamous cell carcinoma. BMC Cancer 8: 34.
- 28. Perrot I, Blanchard D, Freymond N, Isaac S, Guibert B, et al. (2007) Dendritic cells infiltrating human non-small cell lung cancer are blocked at immature stage. J Immunol 178: 2763–2769.
- 29. Thiel A, Pries R, Jeske S, Trenkle T, Wollenberg B (2009) Effect of head and neck cancer supernatant and CpG-oligonucleotides on migration and IFN-alpha production of plasmacytoid dendritic cells. Anticancer Res 29: 3019–3025.
- 30. Naranjo-Gomez M, Oliva H, Climent N, Fernandez MA, Ruiz-Riol M, et al. (2007) Expression and function of the IL-2 receptor in activated human plasmacytoid dendritic cells. Eur J Immunol 37: 1764–1772.
- 31. Umeshappa CS, Huang H, Xie Y, Wei Y, Mulligan SJ, et al. (2009) CD4+ Th-APC with acquired peptide/MHC class I and II complexes stimulate type 1 helper CD4+ and central memory CD8+ T cell responses. J Immunol 182: 193–206.
- 32. Busch A, Quast T, Keller S, Kolanus W, Knolle P, et al. (2008) Transfer of T cell surface molecules to dendritic cells upon CD4+ T cell priming involves two distinct mechanisms. J Immunol 181: 3965–3973.
- 33. Aarstad HJ, Heimdal JH, Klementsen B, Olofsson J, Ulvestad E (2006) Presence of activated T lymphocytes in peripheral blood of head and neck squamous cell carcinoma patients predicts impaired prognosis. Acta Otolaryngol 126: 1326–1333.
- 34. Ara T, Song L, Shimada H, Keshelava N, Russell HV, et al. (2009) Interleukin-6 in the bone marrow microenvironment promotes the growth and survival of neuroblastoma cells. Cancer Res 69: 329–337.
- 35. Kanazawa T, Nishino H, Hasegawa M, Ohta Y, Iino Y, et al. (2007) Interleukin-6 directly influences proliferation and invasion potential of head and neck cancer cells. Eur Arch Otorhinolaryngol 264: 815–821.
- 36. Li YY, Hsieh LL, Tang RP, Liao SK, Yeh KY (2009) Interleukin-6 (IL-6) released by macrophages induces IL-6 secretion in the human colon cancer HT-29 cell line. Hum Immunol 70: 151–158.
- 37. Dasgupta S, Bhattacharya-Chatterjee M, O'Malley BW Jr, Chatterjee SK (2006) Tumor metastasis in an orthotopic murine model of head and neck cancer: possible role of TGF-beta 1 secreted by the tumor cells. J Cell Biochem 97: 1036–1051.
- 38. Uttamsingh S, Bao X, Nguyen KT, Bhanot M, Gong J, et al. (2008) Synergistic effect between EGF and TGF-beta1 in inducing oncogenic properties of intestinal epithelial cells. Oncogene 27: 2626–2634.
- 39. Wilkins-Port CE, Higgins PJ (2007) Regulation of extracellular matrix remodeling following transforming growth factor-beta1/epidermal growth factor-stimulated epithelial-mesenchymal transition in human premalignant keratinocytes. Cells Tissues Organs 185: 116–122.
- 40. Contractor N, Louten J, Kim L, Biron CA, Kelsall BL (2007) Cutting edge: Peyer's patch plasmacytoid dendritic cells (pDCs) produce low levels of type I interferons: possible role for IL-10, TGFbeta, and prostaglandin E2 in conditioning a unique mucosal pDC phenotype. J Immunol 179: 2690–2694.
- 41. Legrand F, Driss V, Woerly G, Loiseau S, Hermann E, et al. (2009) A functional gammadeltaTCR/CD3 complex distinct from gammadeltaT cells is expressed by human eosinophils. PLoS One 4: e5926.
- 42. Zitvogel L, Mignot G, Bonmort M, Ullrich E, Chaput N (2008) [IKDC: killer dendritic cells or antigen-presenting NK cells?]. Med Sci (Paris) 24: 525–528.
- 43. Reizis B (2010) Regulation of plasmacytoid dendritic cell development. Curr Opin Immunol 22: 206–211.
- 44. Schotte R, Rissoan MC, Bendriss-Vermare N, Bridon JM, Duhen T, et al. (2003) The transcription factor Spi-B is expressed in plasmacytoid DC precursors and inhibits T-, B-, and NK-cell development. Blood 101: 1015–1023.
- 45. Scales D, Ni H, Shaheen F, Capodici J, Cannon G, et al. (2001) Nonproliferating Bystander CD4+ T cells Lacking Activation Markers Support HIV Replication during Immune Activation. J Immunol 166: 6437–6443.
- 46. Hartmann G, Krug A, Eigler A, Moeller J, Murphy J, et al. (1996) Specific suppression of human tumor necrosis factor-alpha synthesis by antisense oligodeoxynucleotides. Antisense Nucleic Acid Drug Dev 6: 291–299.
- 47. Garcia-Peydro M, de Yebenes VG, Toribio ML (2006) Notch1 and IL-7 receptor interplay maintains proliferation of human thymic progenitors while suppressing non-T cell fates. J Immunol 177: 3711–3720.
- 48. Bruno L, Res P, Dessing M, Cella M, Spits H (1997) Identification of a committed T cell precursor population in adult human peripheral blood. J Exp Med 185: 875–884.